SavedAdd your journal

Journals / Osteoporoz Dünyasından / 2004 / Cilt: 10 - Sayı: 4

The effects of risedronate therapy combined with vitamin D and calcium on biochemical markers of bone turnover and bone mineral density in postmenopausal osteoporosis

Postmenopozal osteoporozda risedronatın kalsiyum ve D vitamini ile beraber kullanımının kemik döngüsünün biokimyasal belirteçleri ve kemik mineral yoğunluğu üzerine etkisi

Hüsniye KOÇ
Hilal SEKBAN
Cengiz BAHADIR
Nuriye GÜRER
Sacide ATALAY
Can Bora ÖNDER
Pages
161–164
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results demonstrated that risedronate therapy combined with calcium and vitamin D for postmenopausal primary osteoporosis results in significant increases in spinal and femur BMD’s.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of the study was to investigate the effects of risedronate therapy combined with vitamin D and calcium on bone mineral density(BMD) and biochemical markers of bone turnover in patients with primary postmenopausal osteoporosis.
📊
Key Findings & Data:All patients were given daily doses of 5 mg risodronate, 1000 mg elementary calcium and 500 IUvitamine D during 1 year study period.
💡
Conclusion & Impact:Our results demonstrated that risedronate therapy combined with calcium and vitamin D for postmenopausal primary osteoporosis results in significant increases in spinal and femur BMD’s.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç kombinasyonları · Vitamin D · Kalsiyum

Abstract

The aim of the study was to investigate the effects of risedronate therapy combined with vitamin D and calcium on bone mineral density(BMD) and biochemical markers of bone turnover in patients with primary postmenopausal osteoporosis. Fifty osteoporotic postmenopausal women were included in our study. All patients were given daily doses of 5 mg risodronate, 1000 mg elementary calcium and 500 IUvitamine D during 1 year study period. Dual Energy X-ray Absorbsimetry was used for the measurement of BMD’s of the lumbar spine and proximal femur. In addition calcium, magnesium, phosphorus, ALP, tartarat resistant acid phosphotase (TRAP), osteocalcine levels were measured in blood and C-telopeptides(CTX1) in the urine samples . There were no significant changes in serum levels of magnesium, phosphorus and TRAP after one year of therapy. Calcium and ALP levels were lower than baseline. Osteocalcine and CTX levels were found to be decreased significantly. Lomber and proximal femur BMD’s were found to be significantly increased at the end of one year. Our results demonstrated that risedronate therapy combined with calcium and vitamin D for postmenopausal primary osteoporosis results in significant increases in spinal and femur BMD’s. This result was supported by changes in biochemical marker levels of bone turnover as well.

Özet

Çalışmamızın amacı primer postmenopozal osteoporozlu hastalarda risedronatın kalsiyum ve D vitamini ile kombine kullanımının kemik mineral yoğunluğu (KMY) ve kemik döngüsünün biyokimyasal belirteçleri üzerine etkisini araştırmaktı. Çalışmamıza postmenopozal osteoporotik 50 hasta dahil edildi.Tüm hastalara 1 yıllık çalışma süresi boyunca 5mg/gün risedronat, 1000mg/gün elementer kalsiyum ve 500IU Dvitamini verildi. Çalışma öncesi ve sonrası omurga ve proksimal femurdan kemik yoğunluğu ölçümü için Dual Enerji X-Ray absorbsometri kullanıldı. Ayrıca kanda kalsiyum, magnezyum, fosfor, ALP, tartarat rezistan asit fosfataz (TRAP), osteokalsin ve idrar örneklerinde C-telopeptid yıkım ürünleri düzeyleri ölçüldü. Bir yıllık tedavi sonunda magneziyum, fosfor ve TRAP seviyelerinde anlamlı değişiklik yoktu. Kalsiyum ve alkali fosfataz seviyesi başlangıç seviyesinden düşüktü. Osteokalsin ve C-telopeptid yıkım ürünleri seviyesinde anlamlı düşüş tespit edildi. Bir yıl sonunda lomber ve proksimal femur kemik mineral yoğunluklarının anlamlı derecede artmış olduğu tespit edildi. Sonuçlarımız primer postmenopozal osteoporotik hastalarda risedronatla kalsiyum ve D vitamininin kombine kullanımının spinal ve femur KMY ‘nda anlamlı artış yaptığını göstermiştir.Bu sonuç kemik döngüsünün biyokimyasal göstergeleri seviyesindeki değişikliklerle desteklenmektedir

🔖

Cite This Article

KOÇ, H., SEKBAN, H., BAHADIR, C., GÜRER, N., ATALAY, S., ÖNDER, C. B. (2004). The effects of risedronate therapy combined with vitamin D and calcium on biochemical markers of bone turnover and bone mineral density in postmenopausal osteoporosis. Osteoporoz Dünyasından, Cilt: 10 - Sayı: 4, 161–164. https://ajindex.com/articles/286858

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cooper C. Epidemiology of osteoporosis. Osteoporos Int 1999;9(2):2-8
  2. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003; 14(1):2-12
  3. Garnero P, Sornay-Rendu E, Arlot M, Christiansen C, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11(3):337-49
  4. Eastell R, Barton I, Hannon RA, Chines A et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Bone Miner Res 2003;18(6):1051-56
  5. Raisz L, Smith JA, Trahiotis M, Fall P et al. Short-term risedronate treatment in postmenopausal women, effects on biochemical markers of bone turnover. Osteoporosis Int 2000;11(7):615-20
  6. Shiraki M, Fukunaga M, Kushida K, Kishimoto H et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 2003;14(3):225-34
  7. Hosking D, Adami S, Felsenberg D, Andia JC et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003;19(5):383-94
  8. Ravn P, Rix M, Andreassen H, Clemmesen B et al. High bone turnover is assosiated with low bone mass and spinal fracture in postmenopusal women. Calcif Tissue Int 1997;60(3):255-60
  9. Harris ST, Watts NB, Li Z, Chiness AA et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004; 20(5):757-64
  10. Mortensen L, Charles P, Bekker PJ, Digennaro J et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83(2): 396-402
  11. Fukunaga M, Kushida, Kishimoto H, Shiraki M et al. Risedronate Phase III Research Group. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 2002;13(12):971-9
  12. Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract 2002; 8(3): 202-7
  13. Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom 2003;6(1):45-50
  14. Clemmesen B, Ravn P, Zegels B, Taquet A